Who
Connie Matsui
Director
Company insider
Files Form 4 as: Director, Artelo Biosciences; Director, Sutro Biopharma; Director, Halozyme Therapeutics; EVP, Corp. Strategy and Comm., Biogen.
In numbers
- Trades disclosed
- 142
- Buys
- 2
- Sells
- 9
- Bought
- $90K
- Sold
- $16.4M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 18 May 2004
- Last trade
- 17 Jul 2026
- Last filed
- 21 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jul 2026filed 21 Jul 2026 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —136 at $0.00 | filing |
| 17 Jul 2026filed 21 Jul 2026 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —136 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —292 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —292 at $0.00 | filing |
| 23 Dec 2025filed 29 Dec 2025 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,500 at $0.00 | filing |
| 28 Oct 2025filed 30 Oct 2025 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code C | $5.4B38,346 at $140,000.00 | filing |
| 28 Oct 2025filed 30 Oct 2025 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code C | —70,376 | filing |
| 28 Oct 2025filed 30 Oct 2025 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code C | — | filing |
| 28 Oct 2025filed 30 Oct 2025 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code C | — | filing |
| 15 Oct 2025filed 16 Oct 2025 | STRO Sutro BiopharmaBiotechnology | SEC FORM 4 Bought | $40K50,000 at $0.80 | filing |
| 6 Jun 2025filed 10 Jun 2025 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 1 May 2025filed 5 May 2025 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code P | — | filing |
| 20 Dec 2024filed 23 Dec 2024 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,750 at $0.00 | filing |
| 29 Nov 2024filed 3 Dec 2024 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code G | —10,470 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 25 Apr 2024filed 29 Apr 2024 | HALO Halozyme Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,804 at $0.00 | filing |
| 25 Apr 2024filed 29 Apr 2024 | HALO Halozyme TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,501 at $0.00 | filing |
| 28 Feb 2024filed 1 Mar 2024 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,767 | filing |
News
Tenaya Therapeutics (NASDAQ:TNYA) versus Sutro Biopharma (NASDAQ:STRO) Head-To-Head ComparisonSTRO · themarketsdaily.com · 20 Oct 2026Artelo Biosciences, Inc. (NASDAQ:ARTL) Stock Short Interest Climbs 104.7%ARTL · tickerreport.com · 14 Oct 2026Biogen (NASDAQ:BIIB) Hits New 52-Week High Following Analyst UpgradeBIIB · dailypolitical.com · 14 Oct 2026Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?BIIB · insidermonkey.com · 13 Oct 2026Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $2,188,000.00 in StockHALO · themarketsdaily.com · 9 Oct 2026Halozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst SaysHALO · tickerreport.com · 8 Oct 2026
0 headlines in the last 90 days name Connie Matsui; 6 articles from the last 14 days about the 4 companies they traded most, at most three about any one of them.